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Chen).Sequence-specific gene silencing triggered by double-stranded RNA is a fundamental gene regulatory
mechanism present in almost all eukaryotes. Argonaute2 (Ago2) is the central protein component of
RNA-induced silencing complex (RISC), and resides in cytoplasmic processing bodies (P-bodies). In the
present study, we demonstrated one human mutant Ago2 protein containing 6 point mutations
(G32W, F128L, R196Q, P458S, T741A, S752G) failed to accumulate in P-bodies. Analysis of the different
Ago2 revertants indicates the S752 as a key amino acid for P-body localization of Ago2. The S752 is evo-
lutionary conserved in the Piwi domain of Ago2 homologs from worms, insects, plants and mammals. We
further showed the single point mutation S752G interfering the interaction between Ago2 and Dcp1a, a
key component of P-bodies.
 2008 Elsevier Inc. All rights reserved.Programmed mRNA turnover plays an essential role in regulat- ing maturation, miRNA pathway appears to be biochemically indis-
ing gene expression [1]. The major pathway of eukaryotic mRNA
decay is initiated with the deadenylation and followed with decap-
ping by Dcp1/Dcp2 complex [2]. Decapping and degradation of
mRNAs occur in P-bodies [3–5]. RNA interference (RNAi) was first
discovered in the nematode worm Caenorhabditis elegans in
response to double-stranded RNA [6]. Double-stranded RNAs are
recognized by the RNAse III enzyme, Dicer, which cleaves the dou-
ble-stranded RNAs into double-stranded small interfering RNAs
(siRNAs) of 19–21 base pairs [6]. These siRNAs are recognized by
RNA-induced silencing complex (RISC), which unwinds the dou-
ble-stranded siRNAs and guides the siRNA to its target mRNA.
The target mRNA cleaved by the endonuclease Ago2 results in se-
quence-specific gene silencing [7–11]. Ago2 is found to reside pri-
marily in P-bodies and its location facilitates the siRNA-induced
mRNA cleavage by the exonucleases and decapping enzymes
[12,13].
Cells are rarely exposed to siRNAs under natural conditions
except viral infections [14]. However the cleavage or translational
repression of target mRNAs by microRNAs (miRNAs) may become a
common phenomenon in all eukaryotes [12]. miRNAs are a large
family of endogenous, small regulatory RNAs. The nascent tran-
scripts of miRNA genes, pri-miRNAs, are cleaved by Drosha RNase
III endonuclease in nuclei, which define one end of the mature
miRNA. The other end is processed in cytoplasm by Dicer. Follow-ll rights reserved.
hou), chenjm@xmu.edu.cn (J.tinguishable from that of RNAi. A single strand of the miRNA
duplex is incorporated into RISC and directs the RISC to the target
genes. Ago2 is a component of the miRNA-induced translational
repression complex (miRNP), a subtype of RISC. Ago2/miRNP may
direct miRNA-targeted mRNAs to P-bodies to prevent their transla-
tion [13–19]. Ago2 has also been shown to mediate the degrada-
tion of AU-rich mRNA through an miRNA-dependent mechanism
[20].
Ago2 is a member of evolutionary conserved Argonaute protein
family which constitutes proteins involved in a variety of RNA
silencing [21–24]. Ago proteins contain an N-terminal PAZ domain
and a C-terminal PIWI domain [22]. The PAZ domain is a novel RNA
binding module that specifically recognizes the 30 overhang of siR-
NA duplexes [25,26]. The PAZ domain has also been shown to be
critical for miRNAs binding and P-body localization [27]. Liu et al
generated two Ago2 mutant proteins, Ago2-PAZ9 and Ago2-
PAZ10 containing 9 and 10 point mutations, respectively, within
the PAZ domain. Both Ago2-PAZ9 and Ago2-PAZ10 retained the
ability to interact with Dcp1a and Dcp2 but failed to accumulate
in P-bodies [27]. Ago2 is the mediator of small RNA-guided gene-
silencing pathways and localizes to cytoplasmic P-bodies, but there
is little known about how Ago2 is concentrated in P-bodies. We,
here report one human mutant Ago2 protein containing 6 point
mutations (G32W, F128L, R196Q, P458S, T741A, S752G) also failed
to accumulate in P-bodies. We called it Ago2 with 6 mutations
(Ago2-6mut). We produced different revertants of Ago2-6mut by
site-directed mutagenesis and examined the efficiency of the rev-
ertants localizing in P-bodies. The S752 in the PIWI domain
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and the interaction between Ago2 and Dcp1a.
Materials and methods
DNA constructs. Human Ago2 was cloned from HeLa cells using
RT-PCR and Ago2 coding region was subcloned into vector pcD-
NAM with Myc-tag at 30 end. Ago2 mutants were introduced by
site-directed mutagenesis using the QuickChange Kit from Strata-
gene (La Jolla, CA). All plasmids were sequenced by Invitrogen
(Shanghai) and the resulting recombinant plasmid had the desired
mutation(s). GFP-Dcp1a was as previously described [13].
Cell culture and transfection. HeLa and HEK293T cells were cul-
tured in DMEM supplemented with 10% fetal bovine serum,
2 mM glutamine, and 100 ug/ml penicillin and streptomycin in a
37 C incubator with 5% CO2. Cells were transiently transfected
with 2 lg (total) of plasmid DNA per well in 6-well plate using
Lipofectamine 2000 (Invitrogen).
Immunofluorescence. HeLa Cells cultured on coverslips were
fixed in PBS with 4% paraformaldehyde for 10 min at room temper-
ature, permeabilized in PBS containing 0.2% Triton-X100 for 5 min,Fig. 1. The colocalization of wild-type or mutant Ago2 proteins with Dcp1a in HeLa cells
tagged Dcp1a in HeLa cells. Ago2 proteins localized to discrete cytoplasmic foci(P-bodie
Red-conjugated goat anti-mouse IgG antibodies. Dcp1a was visualized by GFP. (A) Imag
10 lm. (B) Co-localization rates of the Ago2 proteins with Dcp1a were calculated and
Ago2(R196Q); 5, Myc-Ago2(P458S); 6, Myc-Ago2(T741A); 7, Myc-Ago2(S752G); 8, My
F128L, R196Q, P458S); 11, Myc-Ago2(G32W, F128L, R196Q, P458S, T741A). In random a
Dcp1a and Myc-Ago2 labeled in Red was calculated. More than 500 cells were counted
represent standard deviation. (For interpretation of the references to color in this figurethen blocked with 5% BSA for 1 h. Cells were incubated with mono-
clonal anti-Myc antibodies (Santa Cruz Biotechnology) for 1 h,
rinsed, and then incubated with Rhodamine-Red-conjugated goat
anti-mouse IgG (Santa Cruz Biotechnology). The samples were
mounted and examined under fluorescent microscope.
Electrophoresis, Western blot, and immunoprecipitation analysis.
Total cell lysates were prepared as previously described for SDS–
PAGE and isoelectric focusing electrophoresis (IEF), respectively
[20,28]. For co-immunoprecipitation, cell lysates prepared as
above were incubated with anti-Myc beads (Sigma) and gently
shaken for 4 h at 4 C. The beads were washed three times with
the lysis buffer. Then, 50 ul SDS sample buffer was added, and
the samples were heated for 5 min at 100 C. The supernatants
were applied to SDS gel and detected by immunoblotting.
Results and discussion
During the investigation of miRNA mediated AU-rich mRNA de-
cay, we cloned human Ago2 from HeLa cells using RT-PCR [20].
Interestingly, we found one mutant Ago2 protein, Ago2-6mut, con-
taining 6 point mutations (G32W, F128L, R196Q, P458S, T741A,. Myc-tagged wild-type (wt) or mutant Ago2 proteins were co-expressed with GFP-
s) by staining with primary mouse anti-Myc antibodies and secondary Rhodamine
es of Myc-Ago2 and GFP-Dcp1 in red and green, respectively; scale bars represent
compared. 1, Myc-Ago2(wt); 2, Myc-Ago2(G32W); 3, Myc-Ago2(F128L); 4, Myc-
c-Ago2(G32W, F128L); 9, Myc-Ago2(G32W, F128L, P458S); 10, Myc-Ago2(G32W,
reas, the cells with GFP discrete foci were selected, the co-localization rate of GFP-
for every experiment and three separate experiments were carried out. Error bars
legend, the reader is referred to the web version of this article.)
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tion or mutations caused the defects of Ago2 in the P-body locali-
zation, we created a series of Ago2 mutants through site-specific
mutagenesis. The resultant plasmids were cotransfected into HeLa
cells with GFP-Dcp1a. GFP-Dcp1a chimeric protein was selected as
a marker of P-bodies [13,27]. The colocalization of the Ago2 pro-
teins and GFP-Dcp1a represented the accumulation of Ago2 in
P-bodies and was visualized by immunofluorescence staining.
We first tested Ago2 with all the 6 single point mutations, respec-
tively, and determined the colocalization rate by counting 500 ran-
domly picked up cells. We observed that the accumulation of
Ago2-S752G in P-bodies significantly decreased (p < 0.01), while
Ago2-G32W, Ago2-F128L, and Ago2-R196Q showed slightly re-
duced colocalization rate with GFP-Dcp1a (Fig. 1A and B). The
S752 appeared to be a key amino acid for Ago2 accumulation in
P-bodies. Then we investigated Ago2 with different combinations
of other 5 mutations (G32W, F128L, R196Q, P458S, T741A) and
all the mutant Ago2 proteins including the one with all five muta-
tions showed slightly lowered localization in P-bodies (columns 7–Fig. 2. The co-localization of GFP-Dcp1a with wt or mutant Myc-Ago2 containing S75
Histograms indicate co-localization rates of GFP-Dcp1a with 1, Myc-Ago2(wt); 2, Myc
Ago2(P458S, S752G); 6, Myc-Ago2(T741A, S752G); 7, Myc-Ago2(G32W, T741A, S752G);
(B) Ago2 with four mutations (G32W, F128L, P458S, S752G) failed to accumulate in P-b11 in Fig. 1 B). Therefore, we concluded that S752 is a critical res-
idue for Ago2 localizing in P-bodies.
Since Ago2-S752G still can accumulate in P-bodies even
though at very low level, we generated a series of Ago2 mutants
all contained S752G and checked their localization in P-bodies.
Addition of all the other point mutations except R196Q on
Ago2-S752G did further decrease the localization rate of the
Ago2 proteins in P-bodies (Fig. 2A and B). Moreover we observed
that Ago2 with the 4 point mutations (G32W, F128L, P458S,
S752G) completely abolished in P-bodies (Fig. 2A and B). We
wondered whether these mutations changed Ago2 expression
level or the protein stability. To exclude these possibilities we
compared the protein level of the Ago2 mutants mentioned above
with that of wild-type Ago2. Western blot assays showed that the
protein levels of the Ago2 mutants were comparable with that of
wild-type Ago2 (Fig. 3A). Taken together, our results suggest that
the mutations we generated probably changed the conformation
of Ago2 and the conformational change suppressed Ago2 localiz-
ing to P-bodies.2G mutation and other mutations. Same standards were applied as in Fig. 1. (A)
-Ago2(S752G); 3, Myc-Ago2(F128L, S752G); 4, Myc-Ago2(R196Q, S752G); 5, Myc-
8, Myc-Ago2(G32W, F128L, P458S, S752G). Error bars represent standard deviation.
odies. Scale bars represent 15 lm.
Fig. 3. The mutant Ago2 proteins expressed at the similar level as wild-type Ago2 and the S752G mutation dramatically reduced the interaction between Ago2 and Dcp1a. (A)
The upper panels show Myc-Ago2 protein expression levels analyzed by Western blotting with anti-Myc antibodies 24 h after transfection. 1, control; 2, Myc-Ago2(wt); 3,
Myc-Ago2(G32W); 4, Myc-Ago2(F128L); 5, Myc-Ago2(R196Q); 6, Myc-Ago2(P458S); 7, Myc-Ago2(T741A); 8, Myc-Ago2(G32W, F128L); 9, Myc-Ago2(G32W, F128L, P458S);
10, Myc-Ago2(G32W, F128L, R196Q, P458S); 11, Myc-Ago2(G32W, F128L, R196Q, P458S, T741A); 12, control; 13, Myc-Ago2(wt); 14, Myc-Ago2(S752G); 15, Myc-Ago2(F128L,
S752G); 16, Myc-Ago2(R196Q, S752G); 17, Myc-Ago2(P458S, S752G); 18, Myc-Ago2(T741A, S752G); 19, Myc-Ago2(G32W, T741A, S752G); 20, Myc-Ago2(G32W, F128L,
P458S, S752G). The lower panels show loading controls blotted with anti-a tubulin antibodies. (B) The interaction between Ago2 and Dcp1a.was shown with co-
immunoprecipitation. GFP-Dcp1a with wt or mutant Ago2 co-expressed in HEK 293T cells. The cells were harvested 24 h after transfection. One-third of the cell lysates was
analyzed by Western blotting with anti-Myc and anti-GFP antibodies. The rest of the cell lysates was subjected to immunoprecipitation with anti-Myc antibodies, and further
analyzed by western blotting with anti-Myc and anti-GFP antibodies as indicated.
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interacts with Dcp1a [27]. We asked whether the mutations in-
volved in Ago2 P-body localization also affect the physical interac-
tion between Ago2 and Dcp1a. Dcp1a was co-expressed with
Ago2(wt), Myc-Ago2(S752G) or Myc-Ago2(G32W, F128L, P458S,
S752G) in HEK 293T cells. The interactions between Dcp1a and dif-
ferent versions of Ago2 were evaluated by co-immnoprecipitation
and Western blot. As shown in Fig. 3B, the single mutation S752G
and 4 mutations (G32W, F128L, P458S, S752G) of Ago2 drastically
decreased the interaction between Ago2 and Dcp1a. It suggests
that S752 of Ago2 is essential in Ago2-Dcp1a interaction. It was
shown previously that Dcp-Ago interactions were resistant to RNa-
seA and occurred even with non-P-body localized Ago2 containing
mutations in that PAZ domain [27]. However RNase eliminates
Ago2 localization in P-bodies [12]. Considered together, it indicates
that the PIWI domain but not the PAZ domain may be required for
Ago2-Dcp1a interaction and such interaction facilitates Ago2 to
localize to P-bodies. Binding to RNAs is not essential for Ago2-
Dcp1a interaction but may be important for Ago2 localizing to
P-bodies.
Recently, Ago2 was shown to be phosphorylated by p38 MAPK
pathway and the phosphorylation of S387 facilitated Ago2 localiza-
tion in P-bodies [29]. The S387A mutation also reduced the locali-
zation of Ago2 to P-bodies. We performed multiple alignments of
Ago2 homologs from different species using online ClustalW pro-
gram (http://www.ch.embnet.org/software/ClustalW.html). The
S387 only exists at the corresponding position in mammalian
Ago2 proteins, whereas S752 is evolutionary conserved in the Piwi
domain of Ago2 homologs from worm, insects, plants and mam-
mals (Fig. S1). We speculated that the S752 might also be a phos-
phorylation site. Wild-type Ago2 and Ago2-S752G or the Ago2
containing 4 point mutations (G32W, F128L, P458S, S752G) were
transiently expressed in HEK293T cells. The cells were treated with
p38 inhibitor SB203580 prior stimulated with Arsenite. Whole cell
lysates were subjected to IEF assay followed by Western blotting to
check the phosphorylation status of the Ago2 proteins. The mutant
Ago2 proteins migrated normally as wild-type Ago2 in IEF assays
(Fig. S2). S752 appears unlikely as a phosphorylation site of
Ago2. Ago2 protein sequence was analyzed with online program
Netphos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/) [30]. In
consistent to the experimental data, S387 appears as a weak phos-
phorylation site while S752 as a non-phosphorylation site (Table.
S1).In an advance online published structure of Ago2, S752 has been
shown to be one of the residues involved in pivot motions between
PAZ and PIWI domains. This closing movement may generate a
narrower nucleic acid binding channel which is necessary to hold
and orient the bound small RNAs [31] (http://www.nature.
com/nature/journal/vaop/ncurrent/abs/nature07315.html). Several
observations in this work indicate that the S752 is critical for the
localization of Ago2 in P-bodies and essential for the interaction
between Argonaute2 and Dcp1a. S752 is highly conserved during
evolution and unlikely to be a phosphorylation site of Ago2.
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